(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...
Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program ...
Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...
With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...
Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...
Shares of Immuneering Corporation (NASDAQ:IMRX) surged 55% following the release of encouraging data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The Cambridge-based ...
Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...
An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.
With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback